# Interventional Oncology Device Market

> Interventional Oncology Devices Market Research Report: Size, Share, Trend Analysis By Applications (Tumor Ablation, Transcatheter Embolization, Biopsy), By Device Type (Ablation Devices, Embolization Devices, Biopsy Devices), By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation), By End Use (Hospitals, Ambulatory Surgical Centers, Cancer Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.21%
- **2024:** $ 3.57 Billion
- **2025:** $ 3.79 Billion
- **2035:** $ 6.92 Billion
- **Key Players:** Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Terumo Corporation (JP), Baxter International (US), Cook Medical (US), AngioDynamics (US), Stryker Corporation (US), Philips (NL)

**Report ID:** MRFR/HC/41083-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/interventional-oncology-device-market-42749

---

## Market Summary

## **Interventional Oncology Device Market Overview**

As per MRFR analysis, the Interventional Oncology Device Market Size was estimated at 3.36 (USD Billion) in 2023. The Interventional Oncology Device Market Industry is expected to grow from 3.57(USD Billion) in 2024 to 6.92 (USD Billion) by 2035. The Interventional Oncology Device Market CAGR (growth rate) is expected to be around 6.21% during the forecast period (2025 - 2035).

### **Key Interventional Oncology Device Market Trends Highlighted**

The Global Interventional Oncology Device Market is experiencing significant growth due to several key market drivers. The increase in the incidence of cancer worldwide has heightened the demand for advanced medical interventions. Additionally, the rise of minimally invasive procedures has made interventional oncology devices more appealing to both healthcare providers and patients, as these methods typically offer quicker recovery times and reduced postoperative pain. Technological advancements in imaging and navigation systems also play a crucial role in enhancing the effectiveness and safety of these procedures. 

As healthcare providers aim to improve patient outcomes, the adoption of innovative interventional oncology devices has become a priority.There are numerous opportunities to be explored in this market. With ongoing research and development efforts, manufacturers can focus on creating hybrid devices that combine multiple treatment modalities. Furthermore, expanding access to healthcare in emerging markets presents significant potential for growth as these regions seek to improve cancer care. 

Collaborations among industry stakeholders, including medical professionals, researchers, and technology companies, can drive innovation and lead to the development of new products that cater to unmet needs in cancer treatment. Recent trends indicate a shift toward personalized medicine, where treatments are tailored based on individual patient profiles.This approach requires the integration of interventional oncology devices with biomarkers and genetic testing to enhance treatment efficacy. 

Additionally, the increasing use of artificial intelligence in procedural planning and execution also represents a notable trend, as it aims to improve precision and outcomes. The focus on patient-centered care and the rise of remote monitoring and telehealth services are further shaping the way interventional oncology is practiced, leading to better management of patients and enhanced follow-ups after procedures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Interventional Oncology Device Market Drivers**

### **Increasing Prevalence of Cancer Cases Worldwide**

The Global Interventional Oncology Device Market Industry is experiencing significant growth fueled by the rising prevalence of cancer cases globally. As more individuals are diagnosed with various forms of cancer, the demand for advanced treatment options is escalating. Interventional oncology devices, including tools and technologies that facilitate minimally invasive treatment procedures, are essential for managing cancer effectively. The projected increase in the number of cancer cases is not only due to factors such as aging populations and lifestyle changes but also advancements in diagnostic techniques that allow for earlier detection of malignancies.

Many patients increasingly need new therapies, which is why it is no surprise that the Global Interventional Oncology Device Market Industry stands to benefit tremendously. The transition from treating using surgical methods to employing interventional oncology devices is a major factor that explains this surge in demand. This is further driven by the strides being made in the research and development of these devices.

Investment in incorporating advanced interventional oncology techniques into treatment protocols is on the rise, which is why the market is growing. Increased focus on interventional oncology-tailored solutions also drives the growth of healthcare practitioners' targeted therapies and personalized medicine concentration, which also plays a critical role in the changing environment of the market.

### **Technological Advancements in Interventional Oncology Devices**

Technological advancements represent a significant driver for the Global Interventional Oncology Device Market Industry. Continuous innovations in device design, imaging technologies, and treatment methodologies contribute to more effective and efficient cancer interventions. These advancements not only improve patient outcomes but also enhance the level of precision and safety during procedures. As new technology emerges, it creates opportunities for manufacturers to develop products that are less invasive, more reliable, and easier to use, fostering greater adoption among healthcare providers and improving the overall efficacy of cancer treatments.

### **Rising Investment in Cancer Research and Development**

The rising investment in cancer research and development is a pivotal factor propelling the Global Interventional Oncology Device Market Industry forward. Governments, private sectors, and non-profit organizations are increasingly directing funds toward innovative cancer treatment technologies, which enhances the development of more sophisticated interventional oncology devices. This financial commitment not only aids in simplifying complex procedures but also promotes collaboration between research institutions and healthcare technology companies to bring advanced patient-centric solutions to market.The ongoing efforts to uncover new potential treatments and improve device capabilities are expected to intensify, further stimulating market growth.

## **Interventional Oncology Device Market Segment Insights**

### **Interventional Oncology Device Market Application Insights**

The Global Interventional Oncology Device Market, particularly within the Application segment, has shown significant potential and is positioned for robust growth in the coming years. By 2024, this market is projected to generate a revenue of 3.57 USD Billion, reflecting the increasing adoption and technological advancements in interventional oncology devices. 

The segmentation of the market into key areas such as [Tumor Ablation](../../../reports/tumor-ablation-market-7139), Transcatheter Embolization, and Biopsy provides a clearer understanding of its dynamics and potential. The Tumor Ablation segment holds a prominent position with a market value of 1.43 USD Billion in 2024 and is expected to grow to 2.66 USD Billion by 2035, highlighting its majority holding in the overall market. Tumor Ablation procedures are significant as they directly target and destroy cancerous cells, which enhances their importance in cancer treatment strategies. 

Transcatheter Embolization is another vital area in the market, with a valuation of 1.21 USD Billion in 2024 and projected growth to 2.32 USD Billion by 2035. This technique is essential as it involves selectively blocking blood flow to tumors, which is critical in managing various types of cancer, thereby solidifying its significant role in the interventional oncology landscape. 

Biopsy, while comparatively smaller in valuation at 0.93 USD Billion in 2024 and expected to reach 1.94 USD Billion by 2035, remains an important application as it plays a crucial role in the diagnostic process, enabling accurate cancer assessments and treatment planning. Each of these applications reflects distinct methodologies and practical implementations, contributing to the overall Global Interventional Oncology Device Market data. The market growth is bolstered by the rising incidence of cancer, advancements in technology, and the increasing preference for minimally invasive procedures. However, challenges such as regulatory hurdles and the high cost of devices may impede growth.

Overall, the ongoing development of these applications promises substantial opportunities for innovation and expansion in the Global Interventional Oncology Device Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Interventional Oncology Device Market Device Type Insights**

The Global Interventional Oncology Device Market is poised for significant growth, with a valuation of 3.57 USD billion in 2024, driven by advancements in technology and an increasing prevalence of cancer. Within the Device Type segment, Ablation Devices, Embolization Devices, and Biopsy Devices hold critical importance. Ablation Devices are widely utilized for their efficacy in targeted destruction of tumor tissues, making them a preferred choice in treatment protocols.

Meanwhile, Embolization Devices play a pivotal role in vascular occlusion, effectively managing blood flow to tumors and demonstrating a significant contribution to the overall market growth.Biopsy Devices serve as essential tools for accurate tumor diagnosis, thereby driving the demand in the market.

The growth of the Global Interventional Oncology Device Market is further supported by rising healthcare expenditures, the need for less invasive procedures, and an increase in research and development activities aimed at innovative device technology. However, considerations such as high treatment costs and regulatory challenges may pose hurdles for market players. Nevertheless, the continuous innovation and expanding application of these devices offer lucrative opportunities in the Global Interventional Oncology Device Market landscape.

### **Interventional Oncology Device Market Technology Insights**

The Global Interventional Oncology Device Market focused on Technology is poised for notable growth, with a projected value of 3.57 billion USD in 2024, expanding to 6.92 billion USD by 2035. This segment consists of various advanced technologies, with Radiofrequency Ablation, Microwave Ablation, and Cryoablation playing significant roles in treatment methodologies. Radiofrequency Ablation is widely adopted due to its effectiveness in tumor destruction, making it a critical component of the market.

Meanwhile, Microwave Ablation is gaining prominence due to its ability to achieve rapid and efficient heat generation during procedures, which increases its application in various cancers.Cryoablation is emerging as an important technique for enhancing patient safety and reducing recovery time, contributing to the overall acceptance of various interventional procedures. Collectively, these technologies drive the ongoing evolution and expansion of the Global Interventional Oncology Device Market, with evolving techniques improving treatment outcomes and patient experiences. Market trends indicate a shift towards minimally invasive procedures, significantly impacting the industry's future and enhancing the potential for growth and innovation.

### **Interventional Oncology Device Market End Use Insights**

The Global Interventional Oncology Device Market is projected to reach a valuation of 3.57 USD Billion by 2024, reflecting strong demand across various end-use segments, primarily among hospitals, ambulatory surgical centers, and cancer research institutes. Hospitals represent a critical area of focus due to their infrastructure and resources to handle complex oncological procedures, often housing advanced interventional oncology devices. Ambulatory surgical centers have gained significance as they offer a convenient and cost-effective alternative for outpatient procedures, catering to the rising number of patients seeking minimally invasive treatments.

Cancer research institutes play a pivotal role in the market as they are centers of innovation, driving advancements in device development and therapeutic techniques, thus enhancing treatment efficacy. The interplay of these end-use segments reveals a market landscape characterized by growth drivers such as increasing cancer prevalence, advances in technology, and a growing emphasis on patient-centric care. However, challenges such as regulatory hurdles and a need for skilled professionals remain relevant. Overall, the Global Interventional Oncology Device Market segmentation highlights substantial opportunities for growth, aligning with emerging health trends and the continuous evolution of oncological therapies.

### **Interventional Oncology Device Market Regional Insights**

The Global Interventional Oncology Device Market revenue shows significant regional diversification, with North America leading with a valuation of 1.25 USD Billion in 2024, which is projected to grow to 2.483 USD Billion in 2035, demonstrating its dominance and significant demand. Europe follows with a valuation of 0.937 USD Billion in 2024, expected to rise to 1.862 USD Billion, reflecting an increasing focus on cancer treatment advancements in the region.

The APAC region, valued at 0.547 USD Billion in 2024 and anticipated to reach 1.086 USD Billion by 2035, indicates considerable growth opportunities driven by a rising incidence of cancer and increased healthcare investments.

In South America, the market is smaller, with a value of 0.312 USD Billion in 2024, expected to grow to 0.621 USD Billion, showcasing gradual market development. The MEA region, valued at 0.523 USD Billion in 2024 and projected to reach 0.869 USD Billion, highlights the growing importance of oncology treatments due to rising healthcare access.

Overall, North America’s majority holding plays a crucial role in the Global Interventional Oncology Device Market segmentation, driving innovation and investment, while other regions also capitalize on emerging opportunities in the oncology space, ultimately contributing to the overall market growth and dynamics in the Global Interventional Oncology Device Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Interventional Oncology Device Market Key Players and Competitive Insights**

The Global Interventional Oncology Device Market is witnessing dynamic competition characterized by an increasing number of players focused on innovation and technological advancement. This sector encompasses a wide range of devices utilized in the diagnosis and treatment of various cancers, including ablation devices, embolization coils, and vascular access devices. With growing incidences of cancer worldwide and the rising demand for minimally invasive treatment options, companies in this market are strategically developing their product portfolios while also investing in research and development activities. 

Competitive strategies such as collaborations, partnerships, and mergers and acquisitions have become prevalent as firms seek to enhance their market share and deliver better services to healthcare providers and patients alike. Abbott Laboratories is recognized for its strong presence in the Global Interventional Oncology Device Market, leveraging its extensive expertise in medical device development and a commitment to enhancing patient outcomes. The company is well-known for its innovative technologies that facilitate cancer treatment, particularly in the domain of interventional oncology. 

Abbott Laboratories has established a robust product portfolio that includes cutting-edge devices designed to minimize procedural risks and improve therapeutic efficacy. With a focus on comprehensive solutions, including procedural planning and imaging technologies, Abbott Laboratories capitalizes on its strengths in both engineering and clinical insight. This enables the company to effectively respond to the growing needs of healthcare practitioners and enhance the overall treatment experience for patients dealing with oncological challenges.

Philips Healthcare also plays a significant role in the Global Interventional Oncology Device Market, particularly known for its advanced imaging and minimally invasive solutions. Philips Healthcare is focused on developing technologies that enable better diagnosis and precise treatment planning in oncology. The company’s strengths lie in its strong brand reputation and commitment to innovation, developing state-of-the-art imaging systems that play a critical role in interventional oncology procedures. By integrating advanced imaging modalities with therapeutic devices, Philips Healthcare enhances procedural accuracy and efficiency, leading to improved patient outcomes.

The company continues to invest heavily in research to stay ahead of market trends and improve its offerings while fostering collaborations that further enhance its capabilities within the interventional oncology landscape.

### **Key Companies in the Interventional Oncology Device Market Include**

- [Abbott Laboratories](https://www.molecular.abbott/us/en/offerings/products/oncology)
- Philips Healthcare
- Terumo Corporation
- RadSource Technologies
- Becton Dickinson
- Varian Medical Systems
- Hologic
- Stryker
- Cook Medical
- Inspire Medical Systems
- Siemens Healthineers
- Boston Scientific
- Bayer
- Medtronic
- Johnson and Johnson

## Interventional Oncology Device Market Industry Developments

- **Q2 2025: IceCure Medical Named Sponsor of Breast Cryoablation Mini Masterclass at 2025 Society of Interventional Oncology Annual Meeting** In February 2025, IceCure Medical Ltd., a pioneer in cryoablation technology, was named sponsor of the Breast Cryoablation Mini Masterclass at the 2025 Society of Interventional Oncology Annual Meeting in Las Vegas, highlighting its non-surgical, freezing-based tumor elimination approach.

## **Interventional Oncology Device Market Segmentation Insights**

### **Interventional Oncology Device Market** **Application** **Outlook**

- Tumor Ablation
- Transcatheter Embolization
- Biopsy

### **Interventional Oncology Device Market** **Device Type** **Outlook**

- Ablation Devices
- Embolization Devices
- Biopsy Devices

### **Interventional Oncology Device Market** **Technology** **Outlook**

- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation

### **Interventional Oncology Device Market** **End Use** **Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes

### **Interventional Oncology Device Market** **Regional** **Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Technological Innovations

Technological advancements play a pivotal role in shaping the market. Innovations such as image-guided therapies, robotic-assisted surgeries, and advanced ablation techniques are transforming the landscape of cancer treatment. For instance, the integration of artificial intelligence in imaging technologies has improved diagnostic accuracy and treatment planning.
 
Furthermore, the market for interventional oncology devices is expected to witness a compound annual growth rate (CAGR) of approximately 8% over the next few years, driven by these technological breakthroughs. As healthcare providers increasingly adopt these cutting-edge solutions, the Interventional Oncology Devices Market is poised for substantial growth, reflecting the ongoing commitment to improving patient outcomes.

### Rising Incidence of Cancer

The increasing prevalence of cancer worldwide is a primary driver for the market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2040, there could be over 27 million new cancer cases annually. This alarming trend necessitates the development and adoption of advanced interventional oncology devices, which are crucial for effective treatment.
 
As healthcare systems strive to manage this growing burden, the demand for innovative devices that facilitate minimally invasive procedures is likely to surge. Consequently, manufacturers are focusing on enhancing their product offerings to meet the needs of healthcare providers and patients alike, thereby propelling the market forward.

### Rising Awareness and Education

The growing awareness and education regarding cancer treatment options are driving the market. As patients become more informed about their treatment choices, there is an increasing demand for effective and less invasive therapies. Educational initiatives by healthcare organizations and advocacy groups are playing a vital role in disseminating information about interventional oncology procedures.
 
This heightened awareness is likely to lead to an increase in patient inquiries and referrals for interventional oncology treatments. Market analysts suggest that as more patients seek out these innovative solutions, the interventional oncology devices market will experience a corresponding growth, reflecting the evolving landscape of cancer care.

### Growing Demand for Minimally Invasive Procedures

The shift towards minimally invasive procedures is significantly influencing the market. Patients and healthcare providers alike are increasingly favoring techniques that reduce recovery time, minimize pain, and lower the risk of complications. This trend is evident in the rising adoption of interventional oncology devices that facilitate procedures such as radiofrequency ablation and cryoablation.
 
Market data indicates that the minimally invasive surgery segment is expected to account for a substantial share of the overall interventional oncology market, driven by patient preference and advancements in technology. As a result, manufacturers are investing in research and development to create devices that align with this demand, further propelling the market.

### Increasing Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a crucial driver for the Interventional Oncology Devices Market. Governments and private entities are allocating significant resources to enhance healthcare facilities, particularly in emerging economies. This investment is aimed at improving access to advanced medical technologies, including interventional oncology devices.
 
As healthcare systems expand and modernize, the demand for innovative treatment options is likely to increase. Reports suggest that the healthcare expenditure in many regions is expected to grow at a rate of 5-7% annually, which will likely benefit the interventional oncology sector. Consequently, this influx of capital is anticipated to stimulate the development and distribution of advanced interventional oncology devices, thereby fostering growth in the market.

## Future Outlook

The Interventional Oncology Devices Industry is projected to grow at a 6.21% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures.

**New opportunities:**

- Development of AI-driven imaging systems for enhanced precision in tumor targeting. Expansion of telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) and follow-up care. Partnerships with healthcare providers for integrated oncology treatment solutions.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs and technological innovations.

## Segment Insights

### By Application: Tumor Ablation (Largest) vs. Transcatheter Embolization (Fastest-Growing)

The market showcases a diverse range of applications, prominently featuring Tumor Ablation, Transcatheter Embolization, and Biopsy. Tumor Ablation is the most established segment, capturing a significant market share due to its widespread utilization in various tumor treatments. Following closely, Transcatheter Embolization has emerged as a critical player, gradually gaining traction and increasing its share in the market due to its unique applications in treating hypervascular tumors and managing bleeding.

Tumor Ablation (Dominant) vs. Transcatheter Embolization (Emerging)

Tumor Ablation remains the dominant application within the Interventional Oncology Devices Market share, characterized by its extensive use of technologies such as radiofrequency, microwave, and cryoablation. The effectiveness of Tumor Ablation in destroying cancer cells while minimizing damage to surrounding tissues positions it as a preferred choice among healthcare providers. In contrast, Transcatheter Embolization is an emerging technique that has shown remarkable growth due to its innovative approach in occluding blood vessels supplying tumors. This technique offers a minimally invasive alternative with fewer complications, making it increasingly popular in clinical settings. As both methods continue to evolve, they symbolize a critical shift towards targeted therapies in interventional oncology.

### By Device Type: Ablation Devices (Largest) vs. Embolization Devices (Fastest-Growing)

In the Interventional Oncology Devices Market, Ablation Devices dominate the landscape, capturing the largest share due to their widespread use in minimally invasive procedures and effective treatment options for tumors. This segment benefits from technological advancements that enhance precision and efficacy, making it a preferred choice among healthcare professionals. In contrast, Embolization Devices are rapidly gaining ground, attributed to increasing demand for organ preservation and less invasive treatment alternatives. Their innovative designs and efficient delivery systems contribute to a notable rise in market share, appealing to a broader patient demographic.

Ablation Devices (Dominant) vs. Biopsy Devices (Emerging)

Ablation Devices stand firmly as the dominant technology in the market. Known for their ability to target and destroy cancer cells with minimal damage to surrounding tissues, these devices are integral in treating various tumor types, particularly in liver, kidney, and [lung cancers](https://www.marketresearchfuture.com/reports/lung-cancer-market-1185). Advances in radiofrequency and microwave ablation techniques ensure higher success rates and faster recovery times, reinforcing their market position. Conversely, [Biopsy Devices](https://www.marketresearchfuture.com/reports/biopsy-devices-market-2250) represent an emerging segment, critical for accurate cancer diagnosis and staging. With growing awareness about early detection of cancer, these devices are witnessing increased adoption, driven by innovations in imaging technologies and needle designs, enhancing their effectiveness and patient safety.

### By Technology: Radiofrequency Ablation (Largest) vs. Microwave Ablation (Fastest-Growing)

In the market, Radiofrequency Ablation captures the largest market share due to its established efficacy and widespread adoption in treating various types of tumors. This technique remains a preferred option among healthcare professionals for delivering targeted therapy, thus solidifying its position in the market. In contrast, Microwave Ablation is gaining momentum, recognized for its rapid heating capabilities and increased treatment efficiency that appeals to both patients and providers.

Technology: Radiofrequency Ablation (Dominant) vs. Microwave Ablation (Emerging)

Radiofrequency Ablation is considered the dominant technology in the Interventional Oncology Devices Market share, primarily due to its long-standing presence and proven patient outcomes. Its techniques are widely understood, making it a popular choice for oncologists. Conversely, Microwave Ablation, as an emerging technology, offers remarkable advantages such as shorter procedure times and potentially better outcomes with larger lesion treatments, paving the way for its rapid adoption. Both techniques showcase a commitment to enhancing patient care and improving therapeutic efficacy in oncology.

### By End Use: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the market, hospitals hold the largest share, attributed to their comprehensive resources and advanced technologies that facilitate complex procedures. This segment has been a primary hub for oncology treatments, leveraging a diverse range of interventional devices for patient care. In contrast, ambulatory surgical centers are rapidly gaining traction, fueled by the increasing preference for outpatient procedures and minimally invasive techniques. Their capacity to provide efficient care at lower costs is driving significant growth in this segment.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals represent the dominant force in the Interventional Oncology Devices Market share due to their extensive infrastructure, specialized workforce, and ability to offer a wide array of oncological treatments. They are equipped with state-of-the-art interventional devices that enable complex procedures, catering to a large patient volume. Conversely, ambulatory surgical centers are emerging as a compelling alternative, characterized by their focus on outpatient care and enhanced patient convenience. These centers have adapted quickly to changing market dynamics by delivering high-quality care at lower operational costs. As a result, they are increasingly favored by patients for procedures that do not require overnight hospitalization, contributing to their rapid expansion in the oncology market.

## Regional Market Share Analysis

North America dominated the global Interventional Oncology Devices Market in 2024, reaching a market size of USD 1.25 Billion. Demonstrating its dominance and significant demand. Europe follows with a valuation of 0.937 USD Billion in 2024, expected to rise to 1.862 USD Billion, reflecting an increasing focus on cancer treatment advancements in the region.

The APAC region, valued at 0.547 USD Billion in 2024 and anticipated to reach 1.086 USD Billion by 2035, indicates considerable growth opportunities driven by a rising incidence of cancer and increased healthcare investments.

In South America, the market is smaller, with a value of 0.312 USD Billion in 2024, expected to grow to 0.621 USD Billion, showcasing gradual market development. The MEA region, valued at 0.523 USD Billion in 2024 and projected to reach 0.869 USD Billion, highlights the growing importance of oncology treatments due to rising healthcare access.

Overall, North America’s majority holding plays a crucial role in the Interventional Oncology Devices Market segmentation, driving innovation and investment, while other regions also capitalize on emerging opportunities in the oncology space, ultimately contributing to the overall market growth and dynamics in the market.

## Competitive Benchmarking

The Global Interventional Oncology Devices Market is witnessing dynamic competition characterized by an increasing number of players focused on innovation and technological advancement. This sector encompasses a wide range of devices utilized in the diagnosis and treatment of various cancers, including ablation devices, embolization coils, and vascular access devices. With growing incidences of cancer worldwide and the rising demand for minimally invasive treatment options, companies in this market are strategically developing their product portfolios while also investing in research and development activities. 
 
Competitive strategies such as collaborations, partnerships, and mergers and acquisitions have become prevalent as firms seek to enhance their market share and deliver better services to healthcare providers and patients alike. Abbott Laboratories is recognized for its strong presence in the market, leveraging its extensive expertise in medical device development and a commitment to enhancing patient outcomes. The company is well-known for its innovative technologies that facilitate cancer treatment, particularly in the domain of interventional oncology. 
 
Abbott Laboratories has established a robust product portfolio that includes cutting-edge devices designed to minimize procedural risks and improve therapeutic efficacy. With a focus on comprehensive solutions, including procedural planning and imaging technologies, Abbott Laboratories capitalizes on its strengths in both engineering and clinical insight. This enables the company to effectively respond to the growing needs of healthcare practitioners and enhance the overall treatment experience for patients dealing with oncological challenges.
 
Philips Healthcare also plays a significant role in the Interventional Oncology Devices Market, particularly known for its advanced imaging and minimally invasive solutions. Philips Healthcare is focused on developing technologies that enable better diagnosis and precise treatment planning in oncology. The company’s strengths lie in its strong brand reputation and commitment to innovation, developing state-of-the-art imaging systems that play a critical role in interventional oncology procedures. 
 
By integrating advanced imaging modalities with therapeutic devices, Philips Healthcare enhances procedural accuracy and efficiency, leading to improved patient outcomes. The company continues to invest heavily in research to stay ahead of market trends and improve its offerings while fostering collaborations that further enhance its capabilities within the interventional oncology landscape.

## Recent News & Developments

- **Q2 2025: IceCure Medical Named Sponsor of Breast Cryoablation Mini Masterclass at 2025 Society of Interventional Oncology Annual Meeting** In February 2025, IceCure Medical Ltd., a pioneer in cryoablation technology, was named sponsor of the Breast Cryoablation Mini Masterclass at the 2025 Society of Interventional Oncology Annual Meeting in Las Vegas, highlighting its non-surgical, freezing-based tumor elimination approach.

## Report Scope

| MARKET SIZE 2024 | 3.569(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 3.79(USD Billion) |
| MARKET SIZE 2035 | 6.923(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.21% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Terumo Corporation (JP), Baxter International (US), Cook Medical (US), AngioDynamics (US), Stryker Corporation (US), Philips (NL) |
| Segments Covered | Applications, Device Type, Technology, End Use, Regional |
| Key Market Opportunities | Integration of advanced imaging technologies enhances precision in the market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Interventional Oncology Device Market by 2035?**
A: The projected market valuation for the Interventional Oncology Device Market by 2035 is 6.923 USD Billion.

**Q: What was the market valuation of the Interventional Oncology Device Market in 2024?**
A: The overall market valuation of the Interventional Oncology Device Market was 3.569 USD Billion in 2024.

**Q: What is the expected CAGR for the Interventional Oncology Device Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Interventional Oncology Device Market during the forecast period 2025 - 2035 is 6.21%.

**Q: Which companies are considered key players in the Interventional Oncology Device Market?**
A: Key players in the Interventional Oncology Device Market include Medtronic, Boston Scientific, Johnson & Johnson, and Terumo Corporation.

**Q: What are the main application segments of the Interventional Oncology Device Market?**
A: The main application segments include Tumor Ablation, Transcatheter Embolization, and Biopsy.

**Q: How much is the Tumor Ablation segment projected to grow by 2035?**
A: The Tumor Ablation segment is projected to grow from 1.5 USD Billion in 2024 to 2.8 USD Billion by 2035.

**Q: What is the projected growth for Ablation Devices in the Interventional Oncology Device Market?**
A: Ablation Devices are expected to grow from 1.427 USD Billion in 2024 to 2.688 USD Billion by 2035.

**Q: What end-use segments are included in the Interventional Oncology Device Market?**
A: End-use segments include Hospitals, Ambulatory Surgical Centers, and Cancer Research Institutes.

**Q: What is the projected market size for Biopsy Devices by 2035?**
A: The market size for Biopsy Devices is projected to increase from 1.064 USD Billion in 2024 to 2.214 USD Billion by 2035.

**Q: How does the market for Transcatheter Embolization devices compare to other segments?**
A: The Transcatheter Embolization segment is projected to grow from 1.2 USD Billion in 2024 to 2.2 USD Billion by 2035, indicating robust growth.

**Q: What is the projected market size of the Global market in 2024?**
A: The Global market is expected to be valued at 2.41 USD Billion in 2024.

**Q: What is the estimated market value for the Global market in 2035?**
A: By 2035, the market is anticipated to reach a value of 5.2 USD Billion.

**Q: What is the expected CAGR for the Global market from 2025 to 2035?**
A: The expected CAGR for this market during the forecast period is 7.24 percent.

**Q: Which region is projected to hold the largest market share for the market in 2024?**
A: In 2024, North America is projected to dominate the market with a valuation of 1.12 USD Billion.

**Q: How much is the market in Europe expected to be worth in 2035?**
A: The market in Europe is estimated to reach a value of 1.61 USD Billion by 2035.

**Q: What will be the market value of Ablation Devices in 2035?**
A: Ablation Devices are expected to have a market value of 1.6 USD Billion in 2035.

**Q: What is the anticipated market growth for Embolization Agents from 2024 to 2035?**
A: The market for Embolization Agents is expected to grow from 0.5 USD Billion in 2024 to 1.1 USD Billion in 2035.

**Q: Who are the major players in the Global market?**
A: Key players in this market include Hologic, AngioDynamics, Johnson and Johnson, and Siemens Healthineers.

**Q: What is the expected growth rate for the APAC region in the market?**
A: The APAC region is expected to grow from 0.38 USD Billion in 2024 to 0.83 USD Billion by 2035.

**Q: What is the market value of Cryoablation Devices in 2024?**
A: In 2024, Cryoablation Devices are valued at 0.26 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/interventional-oncology-device-market-42749*